title: Is all "skin in the game" fair game? The problem with "non-preferred" generics.
authors.affiliation: Policy Analysis Inc, 4 Davis Ct, Brookline, MA 02445. E-mail: goster@pai2.com.
authors.forename: Gerry
authors.initials: G
authors.lastname: Oster
authors.forename: A Mark
authors.initials: AM
authors.lastname: Fendrick
mesh_terms: D017047:Cost Sharing / Q000191:economics; D016527:Drug Costs; D057915:Drug Substitution / Q000191:economics; D016568:Drugs, Generic / Q000191:economics* / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005569:Formularies as Topic; D006801:Humans; D007348:Insurance, Health / Q000191:economics / Q000458:organization & administration; D013810:Therapeutic Equivalency
chemical_list: D016568:Drugs, Generic